拜耳近日宣布，美国FDA已批准其A型血友病（先天性VIII因子缺乏症）治疗药物Jivi（抗血友病因子[重组]，聚乙二醇化-aucl）扩大适用年龄，用于治疗7岁及以上的儿科患者。此前，该药于2018年8月首次获得FDA批准，用于治疗12岁及以上接受过治 ...

拜耳血友病疗法再获FDA批准日前，拜耳（Bayer）公司宣布，美国FDA批准Jivi（重组DNA衍生的长效凝血因子VIII浓缩物）用于7岁及以上血友病A（先天性凝血因子VIII缺乏症）儿科患者。Jivi（BAY94-9027）是一种通过聚乙二醇修饰延 ...

Whippany: Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi, a recombinant DNA-derived, ...

The FDA has extended its approval of Jivi to cover the therapy's use in children with hemophilia A ages 7 years and older.

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and ...

Bayer (BAYRY) announced that the U.S. Food and Drug Administration has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of ...

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.